Guangdong Maijinjia Biotechnologies Co., Ltd. is pioneering the development of Therapeutic Blockmirs in China protected by a broad patent portfolio providing general freedom to operate. While working diligently to establish our inhouse pipeline, we believe in collaborating with Pharma Companies globally to fast track the development of our Blockmirs and reaching the clinic in multiple disease areas simultaneously. MJJ is committed to providing medicine to patients with diseases for which there are currently no treatments.